LEADER 01774nam  2200361   450 
001 9910765745703321
005 20230224115427.0
010   $a3-03842-836-1
035   $a(CKB)5400000000000265
035   $a(NjHacI)995400000000000265
035   $a(EXLCZ)995400000000000265
100   $a20230224d2018      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGlycosaminoglycans and proteoglycans /$fedited by Barbara Mulloy
210  1$aBasel, Switzerland :$cMDPI,$d[2018]
210  4$dİ2018
215   $a1 online resource (v, 215 pages) $cillustrations
320   $aIncludes bibliographical references.
330   $aProteoglycans (PGs) are glycoconjugates in which a protein or peptide core is substituted with polysaccharide chains known as glycosaminoglycans (GAGs). The GAG sidechains carry a significant proportion of the functionality of PGs, interacting with many proteins to form structural units in the extracellular matrix and to modulate the transport and signalling of small proteins acting as morphogens, growth factors and cytokines. Purified GAGs such as heparin and hyaluronan are in common use as therapeutic agents, with many more PG-based natural products, synthetic and semi-synthetic mimetics on the way; in addition, potential therapeutic strategies involving PG/GAG biosynthesis and degradation as targets are currently in development.
606   $aGlycosaminoglycans
615  0$aGlycosaminoglycans.
676   $a599.322
702   $aMulloy$b Barbara
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910765745703321
996   $aGlycosaminoglycans and Proteoglycans$92945089
997   $aUNINA